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Abstract— Computer-based interpretation of medical guide-
lines (GLs) has drawn lots of attention in the past three decades.
It is essential to use a formalism for GLs representation that
would enable the validation of GLs structural properties, be
able to map medical actions into the time scale and support
the automatic formal verification of GLs without additional
translation paths. In this paper we preset a novel approach
based on Timed Automata extended with Tasks (TAT) for
the medical protocol formal representation using the TIMES
toolbox. We discuss the verification issues with the help of the
Imatinib case study.
I. INTRODUCTION
Computer-based interpretation of GLs or medical proto-
cols aimed to assist practitioners in their daily routine can
be classified as tools providing the recommendation for the
structural representation of the medical GL in text form, the
text markup tools, and, finally, decision-support tools that
form the central and the most essential class of the existing
frameworks. These tools help to improve the quality of GLs,
since the initial textual representation of the protocol often
suffers from such structural problems as incompleteness,
inconsistency, ambiguity and redundancy. Moreover, various
decision-support tools are aimed to improve the quality of
medical service by reducing the human factor errors when
providing automatic healthcare recommendations or remind-
ing about some procedures that could have been overlooked.
There have been many frameworks and languages [1]–[5]
developed in the past years in order to assist medical doctors
as well as patients. Many of them such as PRODIGY [2],
EON [1], GLIF3 [3], PROforma [4], SAGE [5] represent
a class of tools used to build complex decision-support sys-
tems. They adapt flow-charts as a core formalism to represent
a sequence of actions that are supported by ontology based
medical terminology interpretation modules. Most of these
tools also provide links to patients’ databases. However,
they enable validation of GLs structure only by means of
their formal representation and have no support for the
automatic verification of their formal properties. There exist
frameworks such as GLARE [6] and Asbru [7] that provide
translation links to model checking environments such as
SPIN [8] and SMV [9]. However, if a verified property fails it
is difficult to trace back the result needed to change the initial
protocol model. Moreover, these formalisms provide the no-
tion of time only in terms of actions order and association of
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time periods with respect to the patient condition evaluation,
which enables only the validation of GLs structure. While,
it is important to be able to map medical actions into the
time scale in order to verify timing properties of a GL
and thus close the gap of medical software and hardware
interoperability.
In this paper we first evaluate the requirements for the pro-
tocol modeling formalism. As a key contribution, we present
a novel approach for the medical protocol formal representa-
tion based on Timed Automaton extended with Tasks (TAT).
TAT is an extension of the Timed Automaton(TA) [10],
an automaton extended with clocks. For protocols formal
representation with TAT we exploit the TIMES toolbox [11],
which is a successor of the UPPAAL [12] toolbox, aimed to
support the modeling and verification of real-time systems.
TIMES includes not only a Graphical User Interface (GUI)
for system modeling but also a model-checker engine that
supports system verification where properties are described
by means of Computational Tree Logic (CTL). It is possible
to connect TAT models with other tools by means of tasks
that can play a role of interfaces, function calls, to some
external environments. The TAT model can also be turned
to a fully synthesizable deterministic model [13] which is
essential when we would like to generate executable code.
We present a case study of modeling the Imatinib dose
adjustment part of the protocol for adult patients with newly
diagnosed Ph+ Chronic Myeloid Leukemia (CML) for whom
bone marrow transplant is not considered as the first line of
treatment. We perform the validation of the protocol structure
as well as discuss issues of the protocol life-cycle properties
verification. In Section II we define the requirements to
the modeling methodology and introduce the TA and TAT
models as our approach. Section III presents the Imatinib
case study and discusses the verification issues.
II. FORMALIZATION APPROACH
Our view to the transformation steps applied to a textual
representation of GLs in the automation process are pre-
sented in Figure 1. The flow starts from a textual docu-
ment summarizing sequence of actions of a GL based on
the experience and medical evidence. In order to choose
an appropriate formalism one should first evaluate all its
potential problems and requirements. We distinguish several
key requirements. First of all it is important to choose a
formalism that has a notion of time and allows modeling of
the choice of sequential actions based on specific conditions
and level of evidence (probabilities) mapped to the time
scale. It should allow the modeling of several plans with pe-
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Fig. 1. General methodology
riodically repeating actions that can be execution in parallel
with other actions. It is also important to be able to associate
some goals with the treatment, e.g. to achieve some effect
or finish some procedure after a period of time. Very often
the initial textual representation of the protocol suffers from:
(i) incompletenesses, (ii) inconsistencies, (iii) ambiguity, and
(iiii) redundancies. Therefore, a chosen formalism should
be able to assist a designer in correcting these problems.
Basically, the first transformation step performs the initial
structural validation of the protocol by representing it using
one of the existing formalisms, since formal representation
can also be considered a formal method by itself.
When the protocol is formally represented it is possible to
perform an automatic verification of the protocol structural
properties, such as the reachability/non reachability of some
states, or to be able to find a path that would avoid certain
actions, e.g. surgery or chemotherapy. This introduces the
requirements to the verification abilities of the methodology.
The central part of Figure 1 shows the verification process.
Moreover, medical software is tightly coupled with the
medical devices that perform the patient state monitoring
and even some basic treatment procedures [14]. Medical
protocols can play a role of an intersection point between
the medical software and electronic devices. Therefore, it is
essential to enable the verification of the timing and life-cycle
properties of the medical protocol. The rightmost step of
Figure 1 represents the synthesis step that may be performed
in two different directions: (i) to produce a decision-support
tool similar to the idea of [15] or to do the code synthesis
for an embedded system as in [16]. Further in the paper we
present TAT as a key formalism for protocols representation.
1) Timed Automata (TA) [10]: is a formal model of
computation often used to describe the execution semantics
of a system and its progress in time. The classical Automaton
is a finite state graph composed of the finite set of loca-
tions Loc and transition relations (edges) ↪→. Each location
may contain a various number of incoming and outgoing
↪→. The location that does not have any incoming ↪→ is
called initial location. The locations that have no outgoing
↪→ are either final or deadlock locations. TA extends the
classical Automaton with the finite set of clocks C and a
set of constraints on these clocks ClockCons(C), where
constraints are conjunctions, disjunctions and negations of
atomic expressions over clocks in the form x ./ n, x ∈
C, n ∈ N0 for ./∈ {<,≤, >,≥,=}. Each location is
characterized by an invariant (I) that specifies a constraint
on a clock under which TA can stay in this location and
which can then enforce a transition to another location.
Formally, Timed Automaton is defined as a tuple TA =
(Loc, Loc0, Act, C, ↪→, I), where Loc is the finite set of
locations, Loc0 ⊆ Loc is the set of initial locations, Act
is a the set of action (transitions labels), C is the finite set
of clocks, ↪→⊆ Loc×ClockCons(C)×Act×2C ×Loc are
its transitions, and I : Loc→ ClockCons(C) is the map of
invariants, which maps locations to clock constraints.
While the invariants of the location the TA currently
resides in hold, time may progress, with all clocks increasing
at the same speed. Transitions within a TA may either change
the current location, or perform a self-loop (	) to the same
location. Transitions are instantaneous and possible at any
time, given that the source location of the transition is marked
active and its guard evaluates to true. The timed model
checker UPPAAL [12], however, implements TA extended
with variables. Similarly to clocks, variables can be used
within guards of edges and location invariants. Upon a
transition, variables can be updated with values. One TA can
describe one instance of a medical protocol. A combination
of medical GLs can be composed from a set of protocol
instances, separate TA cooperating among each other.
2) Cooperating TA: A set of cooperating TA is called
a network of TA. The cooperation mechanism may either
make use of shared (global) variables or be realized as joint
execution of synchronized transitions.
a) Cooperation via shared variables: The values of the
variables declared on the level of a network of TA, can be
read and changed by individual TA.
b) Rendez-vous mechanisms: UPPAAL makes use of
synchronization channels. TA may jointly execute their en-
abled edges if the involved edges carry the same (channel)
identifier a followed by a question or exclamation, marked
a? for the receiver or a! for a sender respectively.
3) Timed Automata Extended with Tasks (TAT): TAT [13]
is an extension of TA with tasks that represent pieces of
code associated with locations of the model. The execution
of a task is triggered by incoming transitions of the location
with the task. Formally, TAT is defined as a tuple TAT =
(Loc, l0, Act,X, ↪→, I,M), where Loc is the finite set of lo-
cations, l0 ⊆ Loc is the initial location, Act is a set of action
(transitions labels), X is the disjoint union of the finite set
of clocks and variables, ↪→⊆ Loc×ClockCons(X)×Act×
2X×M×Loc are its transitions, I : Loc→ ClockCons(X)
is the map of invariants which maps locations to clock and
variable constraints, and M : Act → 2P is a partial (some
actions have no task) function assigning actions with set of
tasks. The execution semantics of TAT is the one of TA
extended with task queues, where tasks are executed upon a
chosen scheduling policy.
III. IMATINIB CASE STUDY
In Figure 2 we present a model of the Imatinib dose
adjustment protocol. It implements the drug administration
part of [17] for adult patients whereby the dose should be
administered once a day (p1 = 1 day).
!action1 
GiveDose 
init1 
t1 < p1 
action2 
Measure 
Init2 
t4 < p4 
init 
chronic_p 
anemia_ch repetitive_anemia 
lack_loss_resp_ch 
anemia_blast anemia_2 pause 
lack_loss_resp_bl 
stop_positive 
!"!#$%"&'()*+,-,
!".#$/"&'()*+,
!"012&3445,,
6'3),$,7,
8!"!9%"%'*:+,-,
!".#$/"%'*:+;,<<,
!"012&3,#,=,,
6'3),$,>77,
8!"!9%"%'*:+,-,
!".#$/"%'*:+;,<<,
!"012&3,9$=,,
6'3),$,?77,
@A"B,$$,/*C),
6'3),$,>77,
1@@"B,$$,/*C),
6'3),$,D77,
E'E"*)3B,$$,/*C),
6'3),$,D77,
E'E"*)3B,$$,/*C),
6'3),$,>775,BF,$,B=,
/G,9$,BG,<<,,
8!"!,#,%"&'()*+H,-,,
!".,#,/"&'()*+H;,
/G,$,75,6'3),$,>77,
/D,9$,BD,<<,,
8!"!,#,%"&'()*+H,-,,
!".,#,/"&'()*+H;,
/D,$,75,6'3),$,?77,
/D,9$,BD,<<,,
8!"!,#,%"&'()*+H,-,,
!".,#,/"&'()*+H;,
/D,$,75,6'3),$,7,
!"!9%"%'*:+H,-,
!".#$/"%'*:+H,
6'3),$,?77,
/F,$$,BF,
/F,$,7,
/>,$$,B>,
/>$,7,
blast_accel 
Fig. 2. Imatinib dose adjustment protocol
The model is a network of three cooperating TATs. The
first TAT of the network consists of two locations (init1 and
action1) and is responsible for the periodic drug delivery.
Thus every period p1 (t1 == p1), TAT is transitioning to the
action1 location. On this transition the clock t1 is reset to 0
and the GiveDose task is activated (added to the scheduling
queue). The transition from the action1 to the init1 location is
then taken. This model would either give a periodic reminder
to a medical doctor to give a dose to a patient or send
a command to a drug delivery device if this process is
fully automated. The second TAT model composed of two
locations represents a periodic action of performing medical
tests, that activates the task of measuring (measure) the level
of neutrophils (N N) and platelets (N T) every period p4 = 14
days (2 weeks). The measure task of this model will update
the values of N N and N T variables of the third, Imatinib
dose adjustment, model that is described below. The original
model is composed of the elements with solid lines only.
The recommended dose of Imatinib is 400 mg/day for
patients in the chronic phase (transition (↪→) from Init to
chronic p) of CML and 600 mg/day for patients in the
accelerated phase (Init ↪→ blast accel) of CML. There-
fore, the first two transitions of the model represent the
choice of the treatment according to the patient condition.
The dose may be increased from 400 mg to 600 mg in
patients with the chronic phase of the disease (chronic p
↪→ lack loss response ch) or from 600 mg to a maximum
of 800 mg given as 400 mg twice daily (blast accel ↪→
lack loss response bl and p1 = p2, where p2 = half day) in
patients with accelerated phase or blast crisis in case of: (i)
disease progression at any time (D p == true); (ii) failure to
achieve a satisfactory hematological or cytogenetic response
(lack r == true); or (iii) loss of a previously achieved
hematological and/or cytogenetic response (loss r == true).
The definition of disease state and response to the treatment
is presented in [18] where levels of the response can be also
represented with a separate network of TAT models.
In the chronic phase of CML, marked with a rectangle in
Figure 2, if the level of neutrophils (ANC) goes below 1.0 x
109/l (N N<=n lowerB) and/or level of platelets goes below
50 x 109/l (N T<=t lowerB):
1) Stop Imatinib until ANC >1.5 x 109/l and platelets
>75 x 109/l (chronic p ↪→ anemia ch);
2) Resume treatment with Imatinib at previous dose, (ane-
mia ch ↪→ chronic p, N fails accounts to the number
of anemia occurances);
3) In the event of recurrence of ANC <1.0 x 109/l
and/or platelets <50 x 109/l, repeat step 1 and resume
Imatinib at reduced dose of 300 mg (anemia ch ↪→
repetitive anemia);
The treatment of a patient in the accelerated phase of
CML or in the blast crisis (starting dose 600 mg) is repre-
sented in the lower part of Figure 2.
A. Verification Issues
The model checking verification of a system requires
that the system is closed, when its behavior is completely
determined by the states of itself. However, some of the
transitions guards of the Imatinib model depend on the
information coming from external models. For example, the
values of level of the neutrophils and platelets is provided
by a model of the patient body reaction to the treatment.
As another example we have the Boolean variables that
determine the disease progression or lack/loss of the re-
sponse. This particular model can be build upon the response
definition presented in [18]. Therefore, the presented model
is an open system, the properties of which should be verified
with respect to any environment, which in turn may be very
uncertain as in case of patients body reaction.
The Module Checking approach presented in [19] suggests
to compose an open system with the maximal environment,
that enables all the external nondeterministic choices, make
the guards that depend on the environment always evaluated
to true. This composition will be a closed system that
contains all possible behaviors of that system combined with
any other environments. Such a composition raises the level
of non-determinism in the model behavior, however, the
model structure remains the same and thus can be verified.
Therefore, we evaluate to true the guards related to the levels
of neutrophils and platelets as well as those related to the
disease state and verify the structural properties of the model.
The entry point in TAT is represented by an initial location
and signifies the beginning of the treatment procedure. The
exit points are the locations that determine the end of
the treatment that can be classified as by having positive,
when the goal of the treatment procedure was achieved, and
negative, when the treatment has failed, results, and thus
the change of the protocol is required. The model above
represents a treatment of a chronic disease, with no positive
result, however, there still should be a positive exit point
(location) to describe even a highly nonprobable case of a
miracle. We artificially added the stop positive location in
the protocol chronic phase reachable from the chronic p and
repetitive anemia locations. The locations lack loss resp ch
and lack loss resp bl play the roles of negative exit points.
Incompleteness problems exists in both the chronic and
the acceleration phases of the model, where once we go to
the repetitive anemia or anemia 2 locations there is either
no outgoing transition (repetitive anemia) or we enter a
closed loop (anemia 2 	 pause). This problem is found
by verifying whether the stop positive or lack loss resp ch
locations are always reachable from chronic p: chronic p–
>E<> (stop positive or lack loss resp ch) and finding the
contrexample leading to the repetitive anemia deadlock lo-
cation. This way, in the chronic phase part of the model we
added a transition repetitive anemia ↪→ lack loss resp ch.
Life-cycle properties verification requires that the modeled
system is complete, including the patient model and should
be verified after the structural protocol verification. There
exist several models of the patient body reaction reflecting
only such a specific aspect as drug concentration in the
blood among which we can name the pharmakokinetical
models [20] or the SVM-based approach [21]. The Imatinib
protocol presented above can not benefit from these models.
However, a novel therapeutic monitoring approach [22] in
the drug administration may be a potential candidate.
IV. CONCLUSIONS
In this paper we have presented a new approach for
computer-based interpretation of the medical protocols that
exploits the Timed Automata extended with Tasks (TAT)
model widely used for the modeling of real-time systems. To
prove the applicability of our approach we have presented the
Imatinib dose adjustment protocol case study. The analysis of
the protocol structure showed incompleteness problem of the
protocol. Several structural problems have been fixed. The
verification of the life-cycle properties of medical protocol
remains an opened question for the moment.
ACKNOWLEDGMENT
The authors would like to thank N. Widmer and V.
Gotta from CHUV Hospital of Lausanne for the discussion
regrading the treatment procedures with Imatinib.
REFERENCES
[1] S. W. Tu and M. A. Musen, “Modeling data and knowledge in the
EON guideline architecture,” Medinfo, vol. 10, no. 1, pp. 280–284,
2001.
[2] P. D. Johnson, S. Tu, N. Booth, B. Sugden, and I. N. Purves, “Using
scenarios in chronic disease management guidelines for primary care,”
in in Proceedings of American Medical Informatics Association(AMIA)
Symposium, pp. 389–93, PubMed Central PMCID, 2000.
[3] A. Boxwala, M. Peleg, S. Tu, O. Ogunyemi, Q. Zeng, D. Wang, V. Pa-
tel, R. Greenes, and E. Shortliffe, “GLIF3: a representation format for
sharable computer-interpretable clinical practice guidelines,” Journal
of Biomedical Informatics, vol. 37, pp. 147–161, June 2004.
[4] D. R. Sutton, P. Taylor, and K. Earle, “Evaluation of PROforma as a
language for implementing medical guidelines in a practical context,”
BMC Medical Informatics and Decision Making, vol. 6, pp. 20+, Apr.
2006.
[5] S. W. Tu, J. R. Campbell, J. Glasgow, M. A. Nyman, R. McClure,
J. McClay, C. Parker, K. M. Hrabak, D. Berg, T. Weida, J. G.
Mansfield, M. A. Musen, and R. M. Abarbanel, “The SAGE Guide-
line Model: Achievements and Overview,” Journal of the American
Medical Informatics Association, vol. 14, pp. 589–598, June 2007.
[6] P. Terenziani, S. Montani, A. Bottrighi, M. Torchio, G. Molino,
and G. Correndo, “The glare approach to clinical guidelines: main
features,” Studies in Health Technology and Informatics, vol. 101,
2004.
[7] G. Duftschmid, S. Miksch, Y. Shahar, and P. Johnson, “Multi-level
verification of clinical protocols,” in in: Proceedings of the Workshop
on Validation Verification of Knowledge-Based Systems (VV98), in
conjunction with the Sixth International Conference on Principles of
Knowledge Representation and Reasoning (KR98, pp. 4–1, 1998.
[8] SPIN. http://spinroot.com/spin/whatispin.html.
[9] SMV. http://www.cs.cmu.edu/ modelcheck/smv.html.
[10] R. Alur and D. L. Dill, “A theory of timed automata,” Theoretical
Computer Science, vol. 126, no. 2, pp. 183–235, 1994.
[11] TIMES. http://www.timestool.com/.
[12] G. Behrmann, R. David, and K. G. Larsen, “A tutorial on Uppaal,” in
Formal Methods for the Design of Real-Time Systems: 4th Intl. School
on Formal Methods for the Design of Computer, Communication, and
Software Systems, SFM-RT 2004, pp. 200–236, Springer, 2004.
[13] T. Amnell, E. Fersman, P. Pettersson, H. Sun, and W. Yi, “Code
synthesis for timed automata,” Nord. J. Comput., vol. 9, no. 4, pp. 269–
300, 2002.
[14] D. Arney, M. Pajic, J. M. Goldman, I. Lee, R. Mangharam, and
O. Sokolsky, “Toward patient safety in closed-loop medical device
systems,” in Proceedings of the 1st ACM/IEEE International Confer-
ence on Cyber-Physical Systems, ICCPS ’10, pp. 139–148, 2010.
[15] I. Porres, E. Domfnguez, B. Perez, A. Rodriguez, and M. Zapata,
“A model driven approach to automate the implementation of clinical
guidelines in decision support systems,” in Engineering of Computer
Based Systems, 2008. ECBS 2008. 15th Annual IEEE International
Conference and Workshop on the, pp. 210 –218, 31 2008-april 4 2008.
[16] B. Kim, A. Ayoub, O. Sokolsky, I. Lee, P. Jones, Y. Zhang, and
R. Jetley, “Safety-assured development of the gpca infusion pump
software,” in Embedded Software (EMSOFT), 2011 Proceedings of
the International Conference on, pp. 155 –164, oct. 2011.
[17] Imatinib. http://www.ema.europa.eu/ema/.
[18] M. Baccarani, F. Castagnetti, G. Gugliotta, F. Palandri, and S. Soverini,
“Response definitions and european leukemianet management recom-
mendations,” Best Pract Res Clin Haematol, vol. 22, no. 3, pp. 331–41,
2009.
[19] O. Kupferman and M. Y. Vardi, “Model checking revisited,” in
Proceedings of the 9th International Conference on Computer Aided
Verification, CAV ’97, (London, UK), pp. 36–47, 1997.
[20] C. Csajka, C. Marzolini, K. Fattinger, L. A. Dcosterd, J. Fellay,
A. Telenti, J. Biollaz, and T. Buclin, “Population pharmacokinetics
and effects of efavirenz in patients with human immunodeficiency
virus infection,” Clinical Pharmacology and Therapeutics, vol. 73,
no. 1, pp. 20–30, 2003.
[21] W. You, N. Widmer, and G. De Micheli, “Example-based support
vector machine for drug concentration analysis,” in Engineering in
Medicine and Biology Society,EMBC, 2011 Annual International Con-
ference of the IEEE, pp. 153 –157, 30 2011-sept. 3 2011.
[22] J. H. Martin, R. Norris, M. Barras, J. Roberts, R. Morris, M. Doogue,
and G. R. D. Jones, “Therapeutic monitoring of vancomycin in
adult patients: a consensus review of the american society of health-
system pharmacists, the infectious diseases society of america, and
the society of infectious diseases pharmacists,” American journal of
health system pharmacy AJHP official journal of the American Society
of HealthSystem Pharmacists, vol. 31, no. 1, pp. 21–24, 2010.
